The phase III , multinational Abatacept Comparison of Sub [ QU ] cutaneous Versus Intravenous in Inadequate Responders to MethotrexatE ( ACQUIRE ) trial comprised a 6-month , randomized , double-blind ( DB ) period , in which patients received intravenous ( IV ) or SC ABA , plus MTX , followed by an open-label , longterm extension ( LTE ) , in which patients received SC ABA , 125 mg/week .